Company Overview and News

2
Anbang prepares to sell overseas assets worth US$10bil

4h thestar.com.my
Former chairman Wu Xiaohui(pic), who masterminded the overseas deal spree, was sentenced in May to 18 years imprisonment for fraud and embezzlement. He is appealing the conviction.
UBS UBS.PRDCL TRI ULSGF

0
ULSGF / UBS AG (OUIDEE43) PS - IDEEL LEVERAGED BUFFERED GS (US90270KSR13) (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908 UBS AG
ULSGF

0
ULSGF / UBS AG TC4621989I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Notes until the Final Terms Supplement, the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Notes, and we are not soliciting offers to buy these Notes, in any
ULSGF

0
ULSGF / UBS AG TC4621989F_1FWP.HTM (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

0
ULSGF / UBS AG TC4621990I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

0
ULSGF / UBS AG TC4621990F_1FWP.HTM (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

0
ULSGF / UBS AG TC4621991I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

0
ULSGF / UBS AG TC4621991F_1FWP.HTM (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

0
ULSGF / UBS AG TC4621992I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

0
ULSGF / UBS AG TC4621992F_1FWP.HTM (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

0
ULSGF / UBS AG TC4621993F_1FWP.HTM (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

0
ULSGF / UBS AG TC4621994I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

0
ULSGF / UBS AG TC4621993I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

0
ULSGF / UBS AG TC4621994F_1FWP.HTM (Prospectus)

7h sec.gov
Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-204908
ULSGF

0
ULSGF / UBS AG TC4621995I_0FWP.HTM (Prospectus)

7h sec.gov
The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement,the Prospectus Supplement, the Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Secur
ULSGF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 0H8923133